Riskpilot← Back to searchSign inGet full accessSTAVANGER SPESIALISTSENTER AS
ASActiveOrg 918468269Hinnasvingene 55, 4020 StavangerMedical specialists activities · NACE 8622Est. 20170 employees
Revenue 2025
NOK 2,1M
+8% vs 2024
EBITDA margin
0.1%
+75% vs 2024
Equity ratio
6.4%
Financial strength
Net profit 2025
NOK 1K
+27% vs 2024
| Revenue | NOK 2,1M | +8% |
| EBITDA | NOK 2K | +75% |
| Net profit | NOK 1K | +27% |
| Total assets | NOK 407K | +40% |
| Equity | NOK 26K | +6% |
| Employees | 0 | — |
Legal name
STAVANGER SPESIALISTSENTER AS
Org number
918468269
Legal form
Aksjeselskap
NACE code
8622 · Medical specialists activities
Founded
28. januar 2017
Share capital
NOK 30 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Styret i fellesskap.
Company purpose
Samordne spesialiserte legetjenester innen fagområdene dermatologi, generell kirurgi, urologi og øye evt ønh, samt lege- og konsulenttjenester som naturlig faller sammen med dette.
Address
Hinnasvingene 55, 4020 Stavanger
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 744 | 1 839 | 1 885 | 1 931 | 2 084 |
| Staff expenses | −7 | −12 | −10 | −9 | −9 |
| EBITDA | 4 | 1 | 0 | 1 | 2 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 4 | 1 | 0 | 1 | 2 |
| Net financials | −1 | −1 | −0 | 0 | −0 |
| Profit before tax | 4 | 0 | 0 | 1 | 2 |
| Tax | −0 | −0 | −0 | 0 | 0 |
| Net profit | 4 | 0 | 0 | 1 | 1 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 161 | 128 | 233 | 291 | 407 |
| Equity | 23 | 23 | 23 | 25 | 26 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 137 | 105 | 210 | 266 | 381 |
| Total debt | 137 | 105 | 210 | 266 | 381 |
EBITDA margin
0.1%
This company
15.8%
Market median
-99% vs market
20212025
Equity ratio
6.4%
This company
38.2%
Market median
-83% vs market
20212025
Return on equity
5.4%
This company
18.4%
Market median
-71% vs market
20212025
Net profit margin
0.1%
This company
8.1%
Market median
-99% vs market
20212025
Asset turnover
5.12×
This company
1.12×
Market median
+357% vs market
20212025
Debt / equity
14.67×
This company
0.62×
Market median
-2266% vs market
20212025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
FH Chief Executive Officer | Chief Executive Officer | 2017 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2017 | |
TB | Board of Directors | 2017 |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 33.33% | 33.33% | 2022 | |
| Company | 33.33% | 33.33% | 2022 | |
| Company | 33.33% | 33.33% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Pål Bjerga Øyelege As
STAVANGER SPESIALISTSENTER AS Board members of STAVANGER SPESIALISTSENTER AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Freddy Hestholm | Chief Executive Officer | 0 companies |
| Pål Bjerga | Board of Directors | 0 companies |
| Tore Bru | Board of Directors | 0 companies |